Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced third quarter 2014 operating and financial results and confirmed 2014 guidance.
“We have made excellent clinical progress over the past quarter, with readouts from both of our Phase 1 studies coming during the next five weeks. For our EZH2 inhibitor EPZ-6438, in August we announced early clinical observations from the ongoing Phase 1 study showing two objective responses among NHL patients enrolled in the first three cohorts of the Phase 1 study.
Help employers find you! Check out all the jobs and post your resume.
“We have made excellent clinical progress over the past quarter, with readouts from both of our Phase 1 studies coming during the next five weeks. For our EZH2 inhibitor EPZ-6438, in August we announced early clinical observations from the ongoing Phase 1 study showing two objective responses among NHL patients enrolled in the first three cohorts of the Phase 1 study.
Help employers find you! Check out all the jobs and post your resume.
